<h4>Aims</h4>To investigate glucose-lowering treatment trajectories preceding glucagon-like peptide-1 receptor agonist (GLP-1RA) initiation in UK primary care, while assessing alignment with contemporary UK clinical guidelines, considering calendar time, cardiovascular disease (CVD) history, and obesity status.<h4>Materials and methods</h4>Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating GLP-1RAs in UK primary care between 01 January 2007 and 30 June 2023. Here, GLP1R is linked to cardiovascular disorder.